Biopharmaceutical distribution and pharmacodynamic evaluation of intra nasal in-situ gel of Lamotrigine for brain targeted drug delivery
Abstract
Background: The present research investigates the nasal delivery of Lamotrigine by incorporating it into a natural in-situ gelling system. Additionally, the retention of the drug in the nasal cavity was enhanced by employing the natural mucoadhesive polymer locust bean gum (LBG). A preliminary investigation was conducted to determine the optimal concentration of gellan gum. The dosage of the drug was calculated using the Robinson Erikson equation. The central composite design was utilized to optimize the influence of individual variables such as gellan gum and locust bean gum on various responses, including gelation time, gel viscosity, mucoadhesive strength, and the time taken for the drug to release half of its initial concentration (t50). The goal of the current study was to evaluate the in-vivo effectiveness of intra nasal in-situ gel of Lamotrigine.
Methodology: The pharmacokinetic and tissue distribution studies were carried out to evaluate the brain targeting efficiency of lamotrigine. Blood samples and tissues of various vital organs like brain, liver, kidneys and heart were obtained at different time intervals, plasma and tissue concentration of Lamotrigine was estimated by reverse phase HPLC.
Results: According to the pharmacokinetic analysis, Cmax and AUC0-α is found to be significantly more (P<0.05) for nasal route compared to oral route. In comparison to the oral route, Cmax and AUC0-α was 7 and 6.5 folds more for IN route. The absolute bioavailability was found to be 159.07%. with regard to the oral group, minimal drug was present in any of the other tissue samples. In the pharmacodynamic data also the formulation through nasal route showed a significant difference compared to oral route (pure drug suspension) delivery in PTZ induced study.
Keywords: Lamotrigine, in-vivo study, tissue distribution, pharmacodynamics
Keywords:
Lamotrigine, in-vivo study, tissue distribution, pharmacodynamicsDOI
https://doi.org/10.22270/jddt.v14i5.6538References
Shah P, Dubey P, Vyas B, Kaul A, Mishra AK, Chopra D, Patel P. Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study. Artificial cells, nanomedicine, and biotechnology. 2021 Jan 1;49(1):511-22. https://doi.org/10.1080/21691401.2021.1939709 PMid:34151674
Allahverdiyev O, Dzhafar S, Berköz M, Yıldırım M. Advances in current medication and new therapeutic approaches in epilepsy. Eastern Journal of Medicine. 2018 Jan 1;23(1). https://doi.org/10.5505/ejm.2018.62534
Abdelmonem R, El-Enin HA, Abdelkader G, Abdel-Hakeem M. Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. Drug Delivery. 2023 Dec 31;30(1):2163321. https://doi.org/10.1080/10717544.2022.2163321 PMid:36579655 PMCid:PMC9809415
Mohan A, Madhavi M, Swetha G, Jyosthna P. Preparation, in vitro and in vivo characterization of solid dispersions of lamotrigine using solvent evaporation technique. IOSR J Pharm. 2015;5(1):54-9.
Ammar HO, Ghorab MM, Mahmoud AA, Higazy IM. Lamotrigine loaded poly-ɛ-(d, l-lactide-co-caprolactone) nanoparticles as brain delivery system. European Journal of Pharmaceutical Sciences. 2018 Mar 30;115:77-87. https://doi.org/10.1016/j.ejps.2018.01.028 PMid:29341900
Joshi AS, Patel HS, Belgamwar VS, Agrawal A, Tekade AR. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation. Journal of Materials Science: Materials in Medicine. 2012 Sep;23:2163-75. https://doi.org/10.1007/s10856-012-4702-7 PMid:22802103
Türker S, Onur E, Ózer Y. Nasal route and drug delivery systems. Pharmacy world and Science. 2004 Jun;26:137-42. https://doi.org/10.1023/B:PHAR.0000026823.82950.ff PMid:15230360
Alexander A, Saraf S. Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of Alzheimer's disease. Neural regeneration research. 2018 Dec 1;13(12):2102-4. https://doi.org/10.4103/1673-5374.241458 PMid:30323136 PMCid:PMC6199953
Dhakar RC, Maurya SD, Tilak VK, Gupta AK, A review on factors affecting the design of nasal drug delivery system. International journal of drug delivery, 2011;3(2)194
Jansson PE, Lindberg B, Sandford PA. Structural studies of gellan gum, an extracellular polysaccharide elaborated by Pseudomonas elodea. Carbohydrate research. 1983 Dec 10;124(1):135-9. https://doi.org/10.1016/0008-6215(83)88361-X
Muller D, Rambo CR, Porto LM, Schreiner WH, Barra GM. Structure and properties of polypyrrole/bacterial cellulose nanocomposites. Carbohydrate polymers. 2013 Apr 15;94(1):655-62. https://doi.org/10.1016/j.carbpol.2013.01.041PMid:23544587
Indira Muzib Y; Aruna kumari D.R; Ramji Ambedkar Y; Design and optimization of lamotrigine in-situ gel for brain targetting via nasal delivery through central composite design. Eur. Chem. Bull, 2023;12:247-268.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy. 2016 Mar;7(2):27. https://doi.org/10.4103/0976-0105.177703 PMid:27057123 PMCid:PMC4804402
Serralheiro A, Alves G, Fortuna A, Falcão A. Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. International journal of pharmaceutics. 2015 Jul 25;490(1-2):39-46.1 https://doi.org/10.1016/j.ijpharm.2015.05.021 PMid:25979854
Muntimadugu E, Dhommati R, Jain A, Challa VG, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease. European journal of pharmaceutical sciences. 2016 Sep 20;92:224-34. https://doi.org/10.1016/j.ejps.2016.05.012 PMid:27185298
Chen Y; Xiao Kuo He; Sun Q; Fang Z; et al., Brain and behaviour, 7, e00727-e00727 (2017).
Parashar P, Diwaker N, Kanoujia J, Singh M, Yadav A, Singh I, Saraf SA. In situ gel of lamotrigine for augmented brain delivery: development characterization and pharmacokinetic evaluation. Journal of Pharmaceutical Investigation. 2020 Jan;50:95-105. https://doi.org/10.1007/s40005-019-00436-0
Published
Abstract Display: 334 
PDF Downloads: 476 PDF Downloads: 49 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.